Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

10-01-2016 | Retinopathy | Review | Article

Surgery for Diabetic Eye Complications

Journal: Current Diabetes Reports

Authors: María H. Berrocal, Luis A. Acaba, Alexandra Acaba

Publisher: Springer US

Login to get access

Abstract

New modalities for the treatment of diabetic eye complications have emerged in the past decade. Nevertheless, many severe diabetic retinopathy complications can only be treated with vitreoretinal surgery. Technological advances in pars plana vitrectomy have expanded the gamut of pathologies that can be successfully treated with surgery. The most common pathologies managed surgically include vitreous opacities and traction retinal detachment. The indications, surgical objectives, adjunctive pharmacotherapy, microincisional surgical techniques, and outcomes of diabetic vitrectomy for proliferative diabetic retinopathy and diabetic tractional retinal detachment will be discussed. With the availability of new microincisional vitrectomy technology, wide angle microscope viewing systems, and pharmacologic agents, vitrectomy can improve visual acuity and achieve long-term anatomic stability in eyes with severe complications from proliferative diabetic retinopathy.
Literature
1.
The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial—Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology. 1988;95:1321–34.CrossRef
2.
The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985;103:1644–52.CrossRef
3.
The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990;108:958–64.CrossRef
4.
The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial- -Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology. 1988;95:1307–20.CrossRef
5.
Fujii GY, De Juan Jr E, Humayun MS, Pieramici DJ, Chang TS, Awh C, et al. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology. 2002;109:1807–12.CrossRefPubMed
6.
Fujii GY, De Juan Jr E, Humayun MS, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology. 2002;109:1814–20.CrossRefPubMed
7.
Eckardt C. Transconjunctival sutureless 23-gauge vitrectomy. Retina. 2005;25:208–11.CrossRefPubMed
8.•
Khan MA, Shahlaee A, Toussaint B, Hsu J, Sivalingam A, Dugel PU, et al. Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease. Am J Ophthalmol. 2016;161:36–43. This study presents results of vitrectomy done with 27g instrumentation for a variety of different pathologies.CrossRefPubMed
9.
da R Lucena D, Ribeiro JA, Costa RA, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009;93:688–91.CrossRefPubMed
10.
Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837–42.CrossRefPubMed
11.
Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Exp Ophthalmol. 2008;36:449–54.PubMed
12.
Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23:108–11.CrossRefPubMed
13.
Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927–38.CrossRefPubMed
14.
Eckardt C, Paulo EB. Heads-up surgery for vitreoretinal procedures: an experimental and clinical study. Retina. 2016;36:137–47.CrossRefPubMed
15.
Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol. 2003;135:169–77.CrossRefPubMed
16.•
Nagiel A, Lalane RA, Sadda SR, Schwartz SD. Ultra-widefield fundus imaging: a review of clinical applications and future trends. Retina. 2016;36:660–78. Ultra-wide field imaging provides a panoramic view of the very peripheral retina. Angiography performed with this technology images areas of the retina not evaluated in the past.CrossRefPubMed
17.
Falkner-Radler CI, Glittenberg C, Gabriel M, Binder S. Intrasurgical microscope-integrated spectral domain optical coherence tomography-assisted membrane peeling. Retina. 2015;35:2100–6.CrossRefPubMed
18.
Robaszkiewicz J, Chmielewska K, Figurska M, Wierzbowska J, Stankiewicz A. Triple therapy: phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of bevacizumab for diffuse diabetic macular edema. Med Sci Monit. 2012;18:CR241–51.CrossRefPubMedPubMedCentral
19.
Berk Ergun S, Toklu Y, Cakmak HB, Raza S, Simsek S. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage. Semin Ophthalmol. 2015;30:177–80.CrossRefPubMed
20.
Michels RG, Rice TA, Rice EF. Vitrectomy for diabetic vitreous hemorrhage. Am J Ophthalmol. 1983;95:12–21.CrossRefPubMed
21.
Chaudhry NA, Lim ES, Saito Y, et al. Early vitrectomy and endolaser photocoagulation in patients with type I diabetes with severe vitreous hemorrhage. Ophthalmology. 1995;102:1164–9.CrossRefPubMed
22.
Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol. 1983;95:22–33.CrossRefPubMed
23.
Arevalo JF, Maia M, Flynn Jr HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213–6.CrossRefPubMed
24.
Arevalo JF, Sanchez JG, Saldarriaga L, et al. Retinal detachment after bevacizumab. Ophthalmology. 2011;118:2304 e3–e7.
25.
Berrocal MH. A minimalist approach to surgery for diabetic retinal detachment new tools allow evolution of surgical techniques. Retina Today. 2014;April:65–68.
26.
Hutton WL, Bernstein I, Fuller D. Diabetic traction retinal detachment. Factors influencing final visual acuity. Ophthalmology. 1980;87:1071–7.CrossRefPubMed
27.
Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic tractionrhegmatogenous retinal detachment. Arch Ophthalmol. 1987;105:503–7.CrossRefPubMed
28.
Yang CM, Su PY, Yeh PT, Chen MS. Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome. Can J Ophthalmol. 2008;43:192–8.CrossRefPubMed
29.
Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic rhegmatogenous retinal detachment. Am J Ophthalmol. 1983;95:34–44.CrossRefPubMed
30.
Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol. 2001;131:44–9.CrossRefPubMed
31.
Hisatomi T, Enaida H, Matsumoto H, et al. Staining ability and biocompatibility of brilliant blue G: preclinical study of brilliant blue G as an adjunct for capsular staining. Arch Ophthalmol. 2006;124:514–9.CrossRefPubMed
32.
Diabetic Retinopathy Clinical Research Network Writing C, Haller JA, Qin H. et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology, 2010;117:1087–1093 e1083.
33.
Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond). 2016;30:463–72.CrossRef
34.
Davis MD. Vitreous contraction in PDR. Arch Ophthalmol. 1965;74:741–51.CrossRefPubMed
35.
Smiddy WE, Feuer W. Incidence of cataract extraction after diabetic vitrectomy. Retina. 2004;24:574–81.CrossRefPubMed
36.
Rice TA, Michels RG, Maguire MG, Rice EF. The effect of lensectomy on the incidence of iris neovascularization and neovascular glaucoma after vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1983;95:1–11.CrossRefPubMed
37.
Jaffe GJ, Lewis H, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol. 1989;108:170–5.CrossRefPubMed
Image Credits